Comprehensive genomic characterization of squamous cell lung cancers Cancer Genome Atlas Research Network Nature 489 (7417), 519, 2012 | 3659 | 2012 |
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2026 | 2016 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1926 | 2014 |
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia DA Landau, SL Carter, P Stojanov, A McKenna, K Stevenson, ... Cell 152 (4), 714-726, 2013 | 1617 | 2013 |
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia L Wang, MS Lawrence, Y Wan, P Stojanov, C Sougnez, K Stevenson, ... New England Journal of Medicine 365 (26), 2497-2506, 2011 | 1384 | 2011 |
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 998 | 2016 |
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 947 | 2018 |
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488, 2012 | 937 | 2012 |
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ... Nature 511 (7511), 616-620, 2014 | 835 | 2014 |
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 VDG Moore, JR Brown, M Certo, TM Love, CD Novina, A Letai The Journal of clinical investigation 117 (1), 112-121, 2007 | 749 | 2007 |
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia JR Brown, JC Byrd, SE Coutre, DM Benson, IW Flinn, ... Blood, The Journal of the American Society of Hematology 123 (22), 3390-3397, 2014 | 736 | 2014 |
A defect in nurturing in mice lacking the immediate early gene fosB JR Brown, H Ye, RT Bronson, P Dikkes, ME Greenberg Cell 86 (2), 297-309, 1996 | 443 | 1996 |
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele … L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ... Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013 | 442 | 2013 |
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 423 | 2019 |
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia A Yoda, Y Yoda, S Chiaretti, M Bar-Natan, K Mani, SJ Rodig, N West, ... Proceedings of the National Academy of Sciences 107 (1), 252-257, 2010 | 404 | 2010 |
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia LZ Rassenti, S Jain, MJ Keating, WG Wierda, MR Grever, JC Byrd, ... Blood, The Journal of the American Society of Hematology 112 (5), 1923-1930, 2008 | 404 | 2008 |
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, ... The Lancet Oncology 17 (10), 1409-1418, 2016 | 394 | 2016 |
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia DA Landau, K Clement, MJ Ziller, P Boyle, J Fan, H Gu, K Stevenson, ... Cancer cell 26 (6), 813-825, 2014 | 381 | 2014 |
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition JA Burger, DA Landau, A Taylor-Weiner, I Bozic, H Zhang, K Sarosiek, ... Nature communications 7 (1), 11589, 2016 | 374 | 2016 |
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 360 | 2021 |